



CIRDAN CAPITAL MANAGEMENT LTD

Summary of the Benchmark Classification and Management Policy and Control Framework

1. Introduction

This Summary is made and published in compliance with Principles 4 and 5 of the Principles for Financial Benchmarks published by the Board of the International Organization of Securities Commissions ("IOSCO Principles") on 17 July 2013 (the "IOSCO Principles") and to adhere to Article 6 of the UKBMR (as defined below).

Cirdan Capital Management Ltd ("Cirdan Capital") acts as Administrator (within the meaning of the UKBMR and/or the IOSCO Principles) of a number of financial indices and strategies that are linked to or referenced by financial products that are manufactured by Cirdan Capital, and which it has identified as "Benchmarks" within the meaning of the IOSCO Principles and the UKBMR.

Cirdan Capital's Benchmark Classification and Management Policy and overall Control Framework (the "Framework") cover the development, determination, operation and governance of the Benchmarks by Cirdan Capital as Administrator.

EUBMR means Regulation 2016/1011 of the European Parliament and of the Council of 8 June 2016 on indices used as benchmarks in financial instruments and financial contracts or to measure the performance of investment funds and amending Directives 2008/48/EC and 2014/17/EU and Regulation (EU) No 596/2014.

UKBMR means the EUBMR as it forms part of "retained EU law" in the United Kingdom as defined in the European Union (Withdrawal) Act 2018 (as amended from time to time).

2. Oversight and Governance

Cirdan Capital's Product Governance Committee and its underlying Index Committee (the "Committee"), are responsible for the overall oversight of activities related to the administration, determination, development, issuance and operation of Benchmarks ("Provision of Benchmarks").

The Committee may delegate its responsibilities as appropriate.

The Committee meets on a periodic basis and has representatives from the front and middle office of the business and the control functions. A summary of the main features of the Committee charter is set out in the Schedule.

3. Main Features of the Framework

a) Creation of New Benchmarks:

New Benchmarks are approved by the Committee which reviews their economic rationale, quality and assess factors such as the integrity, sufficiency and hierarchy of input data, as well as any potential conflicts of interest that may rise during the provision of Benchmarks. Each new Benchmark must also comply with the Benchmark Classification and Management Policy and Procedures to ensure that the relevant internal controls have been applied and approvals received.



b) Investor Disclosures:

The methodology and input data, including the hierarchy of input data, for each Benchmark is documented and made available to counterparties to, or investors in, financial instruments referencing such Benchmarks (the "Investor Disclosure"). The Investor Disclosure includes the content requirements set out in the Framework. Additionally, Cirdan Capital publishes Benchmark Statements for each family/group of Benchmarks it administers, in accordance with the requirements of the UKBMR.

c) Data Integrity:

Cirdan Capital as Administrator, maintains controls and processes to identify and correct input data, including calculation errors or anomalies affecting the published level of a Benchmark. Cirdan Capital also maintains procedures to address business, market, legal, regulatory, judicial, financial or other circumstances that could necessitate or make desirable to effect modifications or changes to Benchmarks.

d) Discretion and Expert Judgement:

Any exercise of discretion or expert judgment is subject to approval by the Committee. If Cirdan Capital is required or entitled to make a determination in relation to a Benchmark pursuant to the Benchmark methodology and that determination involves the exercise of expert judgement or discretion, then it would be exercised in accordance with the provisions of the IOSCO Principles and the UKBMR, as well as the Conflicts of Interest provisions set out in the Framework.

e) Cessation and Transitional Arrangements:

Any discontinuance or termination of a Benchmark will be undertaken in an orderly manner, taking into consideration the potential impact to counterparties to, or investors in, financial instruments referencing such Benchmarks and the integrity of the markets. Other than where there are no outstanding financial instruments linked to a Benchmark, termination of a Benchmark will require escalation, review and approval by the Committee.

f) Oversight of Third Parties:

The Committee monitors on a periodic basis whether third parties involved in the provision of Benchmarks are carrying out their functions effectively and in compliance with the applicable law and regulations.

g) Conflicts of Interests and Information Controls:

In addition to broader Cirdan capital policies on the management of conflicts of interest, in order to monitor and manage potential conflicts of interest in respect of Benchmarks, Cirdan Capital has put in place controls and procedures to mitigate and manage conflicts of interest that may arise during the course of the provision of Benchmarks including:

- to monitor and approve the use of discretion or expert judgment;
- to identify and mitigate personal conflicts of the individuals involved in the provision of Benchmarks;
- to disclose identified existing or potential conflicts of interest within the Investor Disclosures;
- to manage and mitigate conflicts of interest related to trading activities on financial instruments referencing Benchmarks; and
- to safeguard confidential information in relation to the provision of Benchmarks.

h) Retention of records:



Written records in relation to the provision of Benchmarks, including documents relating to complaints, are retained in accordance with applicable legal and regulatory requirements.

j) Complaints:

All complaints relating to Cirdan Capital's Benchmarks, including complaints related to whether a specific benchmark determination is representative of market value, complaints on a proposed change to the benchmark determination process or on an application of the methodology in relation to a specific benchmark determination, and complaints on other decisions in relation to the benchmark determination process, are handled in accordance with Cirdan Capital's Complaints Handling Policy and procedures. These policies and procedures require notification of all complaints to the Compliance function and the Committee and the handling of investigations related to complaints by individuals independent from any personnel who may be or may have been involved in the subject matter of the complaint.

Any complaint relating to a Benchmark should be sent to complaints@cirdancapital.com or usual business contact to Cirdan Capital. All complaints will be investigated and addressed in a timely and fair manner, and the outcome of the investigation will be communicated to the complainant within a reasonable period of time in accordance with Cirdan Capital's Complaints Handling Policy and procedures.

k) Whistleblowing:

Cirdan Capital has an established business integrity program in place, to provide its people and the public with various channels through which integrity concerns can be raised without reprisal. Cirdan Capital prohibits any retaliation for reporting a possible violation of laws, ethics or its policy, no matter whom the report concerns.



Schedule

Main features of the Index Committee Terms of Reference

1. Mission Statement

The Committee:

- (i) oversees the provision of benchmarks by Cirdan Capital;
- (ii) reviews and approves new Cirdan Capital Benchmarks (as defined in the Framework);
- (iii) reviews and provides challenge on the Benchmark determination process, expected or known usage of the Benchmark and the materiality of existing or potential conflicts of interest identified in respect of the Benchmark;
- (iv) oversees the implementation and control infrastructure for such Benchmarks, and the continuing operation of existing Benchmarks, including exercises of discretion by Cirdan Capital in relation thereto; and
- (v) serves as the Oversight Function, under Article 5 of the UKBMR of Cirdan Capital acting as Benchmark Administrators under the UKBMR.

2. Duties and Responsibilities

The duties and responsibilities of the Committee include:

- (i) reviewing and approving new Benchmarks which are implemented by Cirdan Capital as Administrator, in accordance with the Cirdan Capital's Benchmark Classification and Management Policy;
- (ii) reviewing and challenging the economic rationale, quality and integrity of the new Benchmarks being marketed, implemented and traded by Cirdan Capital;
- (iii) reviewing and providing challenge on the Benchmark determination process, including the Benchmark methodology the market or economic reality that the benchmark is intended to measure, expected or known usage of the Benchmark and the materiality of existing or potential conflicts of interest identified;
- (iv) reviewing internal or third party Incidents or adjustment events in the calculation of any Benchmark approved by the Committee after they are notified to the Committee;
- (v) maintaining oversight of and approving the exercise of discretion or expert judgment by Cirdan Capital as Administrator to a Benchmark, including determinations required following Incidents or adjustment events, changes to embedded costs and amendments to the calculation methodology;
- (vi) approving and monitoring the discontinuation or termination of Benchmarks; and
- (vii) considering the results of any internal or external audits and following up on the implementation of remedial actions highlighted in the results of any such audits.

3. Membership



The Chairperson of the Committee defines the size and appoints the members of the Committee (according to skill, expertise and time commitments to the Committee, including understanding of the regulatory requirements applicable to the provision of Benchmarks) and may remove or replace members of the Committee.

The Committee must include representation from the Compliance function. A representative(s) of each core function of Cirdan Capital can be a member of the Committee.

If any Committee member is conflicted in relation to a private interest in any transaction or matter to be considered by the Committee, the Committee member must disclose that interest to the Chairperson and Compliance function, before discussion of the relevant agenda item.